Abstract
High-grade serous ovarian cancer (HGSC) remains a deadly gynecologic malignancy that kills approximately 120 000 women per year worldwide. Despite initial responses to platinum and taxol-based combination therapy in the majority of patients, virtually all HGSC eventually recur as drug resistant disease with very few treatment options. Thus, it is critical to identify novel therapeutic targets and treatment modalities in chemotherapy-resistant HGSC. Here, we describe an approach that combines phenotypic screening in chemoresistant HGSC cell lines with proteome-wide profiling by mass spectrometry in order to deconvolute cellular targets of small molecule inhibitors that can overcome acquired chemotherapy resistance in HGSC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
